This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nikonenko, B. V.
Right arrow Articles by Nacy, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nikonenko, B. V.
Right arrow Articles by Nacy, C. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2004, p. 4550-4555, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4550-4555.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Rapid, Simple In Vivo Screen for New Drugs Active against Mycobacterium tuberculosis

Boris V. Nikonenko,1,2* Rowena Samala,1 Leo Einck,1 and Carol A. Nacy1

Sequella, Inc., Rockville, Maryland,1 Central Research Institute for Tuberculosis, Moscow, Russia2

Received 22 March 2004/ Returned for modification 21 May 2004/ Accepted 18 June 2004

We evaluated the use of a simple and easy-to-obtain potential marker of tuberculosis (TB) drug efficacy, body weight, and correlated weight loss or gain with the number of CFU of Mycobacterium tuberculosis in lungs and spleens of infected mice. C3H mice were infected intravenously with 106 CFU of virulent M. tuberculosis H37Rv, and body weight was evaluated for several weeks after infection. At day 20, infected untreated mice consistently lost more than 25% of their body weight. Chemotherapy with selected orally active anti-TB drugs was initiated 7 days following infection and continued for 13 days. Drugs that were administered daily by gavage included isoniazid (INH), ethambutol (EMB), rifampin (RIF), and moxifloxacin (MXF). At the most effective doses, each of these drugs inhibited bacterial growth and abolished infection-induced body weight loss. Chemotherapy with 1/10 the standard dose of INH determined in accepted long-term murine models of TB also prevented body weight loss, while chemotherapy with 1/10 the standard dose of RIF did not. With only 2 weeks of chemotherapy, we observed a good reverse correlation between CFU in lung or spleen and body weight of mice. The simple measurement of weight in TB-infected drug-treated mice required only a weight balance, and go/no-go drug efficacy data was available on day 20 without the necessity of prolonged drug treatment and long (3 weeks or more) in vitro culture times to obtain organ CFU values.

* Corresponding author. Mailing address: Sequella, Inc., 9610 Medical Center Dr., Suite 200, Rockville, MD 20850. Phone: (301) 762-7776. Fax: (301) 762-7778. E-mail: borisnikonenko{at}sequella.com.

Antimicrobial Agents and Chemotherapy, December 2004, p. 4550-4555, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4550-4555.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Srivastava, V., Manchanda, M., Gupta, S., Singla, R., Behera, D., Das, G., Natarajan, K. (2009). Toll-like Receptor 2 and DC-SIGNR1 Differentially Regulate Suppressors of Cytokine Signaling 1 in Dendritic Cells during Mycobacterium tuberculosis Infection. J. Biol. Chem. 284: 25532-25541 [Abstract] [Full Text]  
  • Nikonenko, B. V., Reddy, V. M., Protopopova, M., Bogatcheva, E., Einck, L., Nacy, C. A. (2009). Activity of SQ641, a Capuramycin Analog, in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 53: 3138-3139 [Abstract] [Full Text]  
  • Sosunov, V., Mischenko, V., Eruslanov, B., Svetoch, E., Shakina, Y., Stern, N., Majorov, K., Sorokoumova, G., Selishcheva, A., Apt, A. (2007). Antimycobacterial activity of bacteriocins and their complexes with liposomes. J Antimicrob Chemother 59: 919-925 [Abstract] [Full Text]  
  • Nikonenko, B. V., Protopopova, M., Samala, R., Einck, L., Nacy, C. A. (2007). Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs. Antimicrob. Agents Chemother. 51: 1563-1565 [Abstract] [Full Text]  
  • Protopopova, M., Hanrahan, C., Nikonenko, B., Samala, R., Chen, P., Gearhart, J., Einck, L., Nacy, C. A. (2005). Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56: 968-974 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»